Skip to search formSkip to main contentSkip to account menu

0.6 ML pegfilgrastim 10 MG/ML Prefilled Syringe [Neulasta]

Known as: PEGFILGRASTIM 6 mg in 0.6 mL SUBCUTANEOUS INJECTION [Neulasta], Neulasta 6 MG per 0.6 ML Prefilled Syringe, 0.6 ML Neulasta 10 MG/ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

8 relations
Acetic AcidNeulastaPolysorbate 20Prefilled Syringe

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim
PurposePegfilgrastim is a long-acting granulocyte colony-stimulating factor indicated for prevention of febrile neutropenia in… 
2017
2017
Assessment of the structure of pegylated‐recombinant protein therapeutics by the NMR fingerprint assay
2017
2017
On‐Body Injector: An administration device for pegfilgrastim
&NA; Many chemotherapy regimens used today require the support of a granulocyte‐colony‐stimulating factor for the prevention of… 
2017
2017
Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States
Abstract Introduction: Granulocyte colony-stimulating factors (G-CSFs), when used to reduce the incidence, severity, and duration… 
2013
2013
Wirksame Phytopharmatherapie bei Zystitis
— Beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) sind dank neuer Therapiestrategien wie der sequenziellen… 
2013
2013
Risiko für febrile Neutropenien beachten
— Beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) sind dank neuer Therapiestrategien wie der sequenziellen… 
2012
2012
Critical appraisal of biosimilar filgrastim (Nivestim™) for febrile and chemotherapy-induced neutropenia
Recombinant granulocyte colony-stimulating factor (filgrastim) stimulates the proliferation and differentiation of hematopoietic… 
2005
2005
P110 Pegfilgrastim (Neulasta®) Enables Delivery of FEC 100 Chemotherapy in Elderly Subjects with High Risk Breast Cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)